CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 314 enrolled
Drug / intervention
telmisartan+amlodipine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00550953
NCT00550953Phase 3Completed
CompareCT.gov

Filtered Trial for Telmisartan 40mg Non-responder

Boehringer Ingelheim·interventional·Posted Oct 30, 2007·Updated Jan 30, 2014

In Brief

A Phase 3 clinical trial evaluating telmisartan+amlodipine and telmisartan for Hypertension. Completed, enrolled 314 participants across 5 sites.

Detailed Summary

The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.7 years ago

Interventions

telmisartan+amlodipinedrug

telmisartandrug